Treme Bio offers ProLymph Nano, a biodegradable polymer platform that delivers a wide range of therapeutics directly to the lymphatic system with controlled release over days to weeks. The technology enables pharmaceutical and biotech companies to achieve sustained dosing and improved exposure for lymphatic‑related diseases while supporting scalable, cost‑effective manufacturing.
Funding
Funding not disclosed
Founders
Product
Problem
Therapeutic agents targeting the lymphatic system often suffer from poor dosing precision and limited residence time due to the network’s unique structure, making it difficult to achieve sustained therapeutic levels for lymphatic‑related diseases.
Solution
ProLymph Nano is a patented drug delivery platform that enables sustained release of a wide range of active molecules directly into the lymphatic network. The system is built from biodegradable, biocompatible materials that can be manufactured at scale and formulated economically. By delivering therapeutics over days to weeks, ProLymph Nano reduces the need for frequent dosing and improves exposure at the intended site of action, addressing the dosing challenges inherent to lymphatic pathologies.
Target Audience
Primary customers are pharmaceutical and biotech companies developing therapies for lymphatic‑related diseases, as well as contract development and manufacturing organizations seeking a lymphatic‑targeted delivery solution.
Features
- Biodegradable and biocompatible polymer matrix designed for lymphatic uptake
- Supports diverse molecular payloads, including small molecules, peptides, and biologics
- Formulation process compatible with commercial‑scale manufacturing
- Controlled release kinetics providing days‑to‑weeks of therapeutic exposure
- Economical production cost due to simple manufacturing workflow